NCT lookup

Inclusion Criteria:

* Healthy Chinese male subjects, aged 20-45 years inclusive at the time of screening
* Chinese subjects must have Chinese parents and grandparents, all of whom were born in China
* A body mass index (BMI) between 19 and 24 kilograms per height in meters squared (kg/m\^2), inclusive
* Able to participate and willing to give written informed consent and to comply with the study requirements

Exclusion Criteria:

* Any history or presence of a clinically significant disorder, or any other condition or disease which in the judgement of the investigator would place the subject at undue risk; interfere with absorption, distribution, metabolism, and excretion of emicizumab; or interfere with the ability of the subject to complete the study
* Major illness within 1 month prior to dosing, and/or any condition which could relapse during or immediately after the study
* Use of any prescribed or over-the-counter (OTC) medication or herbal medicine taken within 14 days prior to dosing or within 5 times the elimination half-life of the medication prior to dosing (whichever is longer), with some exceptions
* Any significant donation/loss of blood or plasma (greater than 450 milliliters) within the 3 months prior to dosing
* Regular smoker with consumption of more than 10 cigarettes per day or the equivalent amount of tobacco
* Participation within a clinical study with an investigational drug or device within the last 3 months prior to dosing
* Any clinically relevant history of hypersensitivity or allergic reactions, either spontaneous or following drug administration or exposure to foods or environmental agents
* Previous or concomitant thromboembolic disease such as deep vein thrombosis (DVT) or signs of thromboembolic disease, or family history of thromboembolic disorder such as serious DVT
* At high risk for thrombotic microangiopathy (e.g., have a previous medical or family history of thrombotic microangiopathy), in the investigator's judgment
* Previous or concomitant autoimmune or connective tissue disease
* History of tuberculosis or active tuberculosis with positive test result at screening
* Any other reason that, in the judgment of the investigator, would render the subject unsuitable for study participation

• Beijing, China